Home Oxygen for COPD: What the Trials Actually Show

Long-term home oxygen adds years to life in COPD for one narrowly defined group: people whose blood oxygen is severely low even while sitting at rest. Everything the trials tell us follows from that single fact. Two studies from around 1980 showed the survival benefit in patients with severe resting hypoxemia, and when a large 2016 trial tested oxygen in a milder group, the benefit vanished. Home oxygen turns out to be a treatment for a measured, sustained deficit, not a response to a monitor that occasionally dips into the low 90s.

Key points#

• The survival benefit of home oxygen is proven only for severe resting hypoxemia (roughly a resting PaO2 at or below 55 mmHg, or an SpO2 at or below 88 percent).
• The 2016 LOTT trial tested oxygen in people with moderate resting or exercise-only desaturation and found no benefit for survival, hospitalization, or quality of life.
• Eligibility rules are anchored to objective, resting measurements, not to a single alarming reading on a fingertip oximeter.
• Home oxygen carries real burdens, so the threshold matters.

Start with the physiology#

To read the trials correctly you need to know why any threshold exists at all. The answer is the shape of the oxyhemoglobin dissociation curve, the relationship between the oxygen tension in arterial blood (PaO2) and how much oxygen hemoglobin actually carries.

Across a wide upper range, that curve is nearly flat. Hemoglobin stays almost fully loaded, so adding oxygen raises the number on a monitor without changing much of what reaches tissue. Then, once PaO2 falls below roughly 60 mmHg (near an oxygen saturation of about 90 percent), the curve turns steep. Below that shoulder, each further drop in PaO2 strips away a large share of the oxygen delivered to the heart, brain, and kidneys.

Sustained hypoxemia in that steep zone sets off a slow cascade: the blood vessels in the lungs constrict, the right side of the heart strains against the higher pressure, and the body makes extra red cells to compensate. Reversing that cascade is the job supplemental oxygen was shown to do. That is why long-term oxygen eligibility sits near a resting PaO2 of 55 mmHg rather than at some rounder, more intuitive number.

The two trials that set the line#

Two studies from the late 1970s built the evidence base, and both enrolled patients who were already severely hypoxemic. That shared starting point is the key to interpreting them.

MRC: oxygen versus no oxygen#

The Medical Research Council Working Party trial, published in The Lancet in 1981, asked the more basic question first: does oxygen help at all? Its 87 patients had chronic bronchitis or emphysema with severe hypoxemia, carbon dioxide retention, and a history of heart failure. Half received oxygen for at least 15 hours a day; the rest got none. Over five years, 19 of 42 oxygen-treated patients died, compared with 30 of 45 in the control group. The survival curves did not pull apart until roughly 500 days had passed. Oxygen worked, but slowly, and only in people who were profoundly hypoxemic to begin with.

NOTT: more oxygen versus less#

The Nocturnal Oxygen Therapy Trial, reported in the Annals of Internal Medicine in 1980, took the next step. Its 203 patients qualified with a PaO2 at or below 55 mmHg, or at or below 59 mmHg alongside a sign of right-heart strain such as ankle swelling, a raised red-cell count (hematocrit of 55 percent or more), or electrocardiographic evidence of pulmonary hypertension. Everyone received oxygen; the question was how much. One group used it continuously, about 18 hours a day, the other only overnight, about 12 hours. Mortality in the nocturnal-only group ran close to twice that of the continuous group. NOTT never tested whether to give oxygen at all. Within a severely hypoxemic population, it showed that more hours saved more lives.

The 2016 trial that mapped the boundary#

For decades one question stayed open: what about the much larger group who fall short of those strict criteria, the patients with only moderate desaturation? The Long-Term Oxygen Treatment Trial (LOTT), published in the New England Journal of Medicine in 2016, was built to answer it.

Its 738 participants had stable COPD with either moderate resting desaturation (SpO2 of 89 to 93 percent) or desaturation only during effort (SpO2 dropping below 90 percent on a six-minute walk test). They were randomized to long-term supplemental oxygen or to none. The result was flat: no significant difference in time to death or first hospitalization (hazard ratio 0.94, 95 percent confidence interval 0.79 to 1.12). Oxygen also failed to improve quality of life, lung function, walking distance, or the rate of COPD flare-ups. LOTT did not contradict the older trials; it drew the outer edge of the same map, confirming that the benefit seen in NOTT and MRC does not extend outward to milder disease.

How the guidelines read today#

Eligibility for long-term oxygen therapy still rests on the thresholds those early trials established. Guideline bodies recommend continuous oxygen for a resting PaO2 at or below 55 mmHg, or an SpO2 at or below 88 percent, and for the narrow band of patients at 56 to 59 mmHg who also show cor pulmonale, edema, or a high red-cell count, the same secondary criteria NOTT used. LOTT reinforced that framework by showing what lies just past its border: added cost and burden without measurable gain.

Why a dipping oximeter is not the trigger#

Put together, the three trials tell a coherent story. Supplemental oxygen treats severe, sustained hypoxemia, and it is measured at rest. It is not a fix for a single low reading and not a way to buy reassurance from a higher number on your fingertip monitor.

That distinction carries weight because home oxygen is not free of downside. It tethers you to equipment, raises fire and burn risk near open flames, limits mobility, and can make you look sicker than the evidence says. An oximeter that drifts into the low 90s overnight or during a walk can feel alarming, yet LOTT showed that treating that pattern with oxygen neither lengthened life nor cut hospital stays. None of this means oxygen is minor. It means its proven benefit is concentrated in a group defined by objective, resting numbers.